The activity of vancomycin against heterogeneous vancomycin-intermediate methicillin-resistant Staphylococcus aureus explored using an in vitro pharmacokinetic model

scientific article published in November 2001

The activity of vancomycin against heterogeneous vancomycin-intermediate methicillin-resistant Staphylococcus aureus explored using an in vitro pharmacokinetic model is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1093/JAC/48.5.727
P698PubMed publication ID11679564

P2093author name stringTurner J
Bennett PM
MacGowan AP
Wootton M
Howe RA
Salisbury V
Holt HA
Bowker KE
Walsh TR
P433issue5
P407language of work or nameEnglishQ1860
P921main subjectStaphylococcus aureusQ188121
pharmacokineticsQ323936
vancomycinQ424027
methicillin-resistant Staphylococcus aureusQ595158
P1104number of pages4
P304page(s)727-730
P577publication date2001-11-01
P1433published inJournal of Antimicrobial ChemotherapyQ6294770
P1476titleThe activity of vancomycin against heterogeneous vancomycin-intermediate methicillin-resistant Staphylococcus aureus explored using an in vitro pharmacokinetic model
P478volume48

Reverse relations

cites work (P2860)
Q40542104Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus
Q40326741In vitro pharmacodynamics of vancomycin and cefazolin alone and in combination against methicillin-resistant Staphylococcus aureus
Q44758945Linezolid in VAP by MRSA: a better choice?
Q37287797Molecular Epidemiology of a Vancomycin-Intermediate Heteroresistant Staphylococcus epidermidis Outbreak in a Neonatal Intensive Care Unit.
Q41925060Pharmacodynamics of telavancin studied in an in vitro pharmacokinetic model of infection
Q43433837Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility

Search more.